Eli Lilly has given hospitals until May 18 to submit comprehensive claims data for continued access to discounted drugs under the 340B program, threatening loss of benefits if compliance is not met.
Eli Lilly has issued a stern deadline to approximately 50 hospitals participating in the federal 340B drug discount program. The company is demanding that these institutions submit detailed claims data within the next five days or risk losing their mandated price breaks. This ultimatum comes after Eli Lilly implemented a new policy last January, requiring such data to curb what it perceives as duplicate discounts paid to participating hospitals.
The move has sparked tension in the pharmaceutical industry and intensified an ongoing dispute between hospitals and drug manufacturers over the 340B program. For several years now, more than 2,300 hospitals have adhered to Eli Lilly’s demands. However, some of the larger hospital systems across the United States have defied the policy despite multiple follow-up letters sent by Derek Asay, senior vice president for government strategy and federal accounts at Eli Lilly.
Asay the deadline is part of a broader effort to ensure compliance with Eli Lilly's new requirements. "We are giving hospitals until May 18 to submit their claims data," he explained. "Failure to do so will result in the loss of their 340B drug discounts."
The 340B program aims to provide discounted drugs to safety-net hospitals that serve a significant number of low-income patients. However, Eli Lilly argues that some hospitals are receiving duplicate discounts, which it believes is unfair and unsustainable.
Hospitals argue that collecting the necessary data is burdensome and time-consuming. They contend that the policy imposes an undue administrative burden on them without providing adequate support or resources to comply. The dispute has led to a protracted legal battle, with both sides vying for control over how the program operates.
The deadline set by Eli Lilly underscores the growing tension between pharmaceutical companies and hospitals regarding the 340B drug discount program. As the deadline looms, it remains to be seen whether hospitals will comply or continue their resistance against the new policy.
